Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Rating of “Hold” from Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has received a consensus recommendation of “Hold” from the ten research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $6.8071.

A number of analysts have recently commented on the company. D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a research note on Friday. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Lake Street Capital dropped their price objective on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd.

Institutional Investors Weigh In On Pulmonx

Several hedge funds have recently modified their holdings of the company. Cerity Partners LLC purchased a new position in shares of Pulmonx in the 4th quarter valued at about $27,000. FNY Investment Advisers LLC acquired a new stake in Pulmonx in the third quarter valued at approximately $29,000. Opal Capital LLC purchased a new stake in shares of Pulmonx in the fourth quarter valued at approximately $29,000. Regatta Capital Group LLC purchased a new stake in shares of Pulmonx in the fourth quarter valued at approximately $30,000. Finally, Jain Global LLC acquired a new position in shares of Pulmonx during the 3rd quarter worth approximately $30,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Price Performance

NASDAQ:LUNG opened at $1.51 on Monday. The firm’s fifty day moving average is $1.92 and its two-hundred day moving average is $1.79. The firm has a market cap of $62.08 million, a price-to-earnings ratio of -1.07 and a beta of 0.07. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. Pulmonx has a one year low of $1.31 and a one year high of $9.35.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.